Litcius/Paper detail

Anakinra Activates Superoxide Dismutase 2 to Mitigate Inflammasome Activity

Marilena Pariano, Stefania Pieroni, Antonella De Luca, Rossana G. Iannitti, Monica Borghi, Matteo Puccetti, Stefano Giovagnoli, Giorgia Renga, Fiorella D’Onofrio, Marina Maria Bellet, Claudia Stincardini, Maria Agnese Della Fazia, Giuseppe Servillo, Frank L. van de Veerdonk, Claudio Costantini, Luigina Romani

2021International Journal of Molecular Sciences27 citationsDOIOpen Access PDF

Abstract

Inflammasomes are powerful cytosolic sensors of environmental stressors and are critical for triggering interleukin-1 (IL-1)-mediated inflammatory responses. However, dysregulation of inflammasome activation may lead to pathological conditions, and the identification of negative regulators for therapeutic purposes is increasingly being recognized. Anakinra, the recombinant form of the IL-1 receptor antagonist, proved effective by preventing the binding of IL-1 to its receptor, IL-1R1, thus restoring autophagy and dampening NLR family pyrin domain containing 3 (NLRP3) activity. As the generation of mitochondrial reactive oxidative species (ROS) is a critical upstream event in the activation of NLRP3, we investigated whether anakinra would regulate mitochondrial ROS production. By profiling the activation of transcription factors induced in murine alveolar macrophages, we found a mitochondrial antioxidative pathway induced by anakinra involving the manganese-dependent superoxide dismutase (MnSOD) or SOD2. Molecularly, anakinra promotes the binding of SOD2 with the deubiquitinase Ubiquitin Specific Peptidase 36 (USP36) and Constitutive photomorphogenesis 9 (COP9) signalosome, thus increasing SOD2 protein longevity. Functionally, anakinra and SOD2 protects mice from pulmonary oxidative inflammation and infection. On a preclinical level, anakinra upregulates SOD2 in murine models of chronic granulomatous disease (CGD) and cystic fibrosis (CF). These data suggest that protection from mitochondrial oxidative stress may represent an additional mechanism underlying the clinical benefit of anakinra and identifies SOD2 as a potential therapeutic target.

Topics & Concepts

SOD2AnakinraInflammasomeOxidative stressSuperoxide dismutaseNALP3Pyrin domainBiologyInflammationReactive oxygen speciesImmunologyCancer researchCell biologyPharmacologyMedicineBiochemistryInternal medicineDiseaseInflammasome and immune disordersHeme Oxygenase-1 and Carbon MonoxideChronic Obstructive Pulmonary Disease (COPD) Research
Anakinra Activates Superoxide Dismutase 2 to Mitigate Inflammasome Activity | Litcius